Market Cap ₹9568 Cr.
Stock P/E 54.2
P/B 7.3
Current Price ₹1459.3
Book Value ₹ 199.9
Face Value 10
52W High ₹1759
Dividend Yield 0.07%
52W Low ₹ 1069.5
Jupiter Life Line Hospitals Ltd is a leading healthcare institution renowned for its commitment to quality patient care and medical excellence. Founded on a mission to provide comprehensive healthcare services, Jupiter Life Line Hospitals boasts a network of state-of-the-art medical facilities equipped with cutting-edge technology and staffed by a dedicated team of healthcare professionals. Specializing in a wide range of medical specialties, including cardiology, orthopedics, oncology, and more, the company prioritizes patient well-being and offers personalized treatment plans to meet each individual's unique needs. With a patient-centric approach and a reputation for delivering outstanding medical outcomes, Jupiter Life Line Hospitals Ltd is a trusted destination for those seeking top-tier healthcare services.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 221 | 228 | 242 | 243 | 263 | 273 | 290 | 287 | 323 | 321 |
| Other Income | 3 | 2 | 3 | 5 | 4 | 8 | 9 | 8 | 9 | 8 |
| Total Income | 224 | 231 | 246 | 248 | 267 | 281 | 299 | 295 | 332 | 329 |
| Total Expenditure | 166 | 183 | 191 | 190 | 202 | 211 | 228 | 223 | 248 | 246 |
| Operating Profit | 58 | 48 | 55 | 58 | 65 | 70 | 71 | 72 | 84 | 83 |
| Interest | 10 | 11 | 11 | 12 | 12 | 1 | 1 | 1 | 1 | 3 |
| Depreciation | 10 | 10 | 10 | 11 | 11 | 11 | 10 | 11 | 14 | 14 |
| Exceptional Income / Expenses | -0 | 0 | -2 | -1 | -1 | -0 | 2 | 0 | 0 | 0 |
| Profit Before Tax | 38 | 27 | 32 | 34 | 41 | 58 | 62 | 60 | 69 | 67 |
| Provision for Tax | 11 | 27 | 16 | -20 | 8 | 14 | 17 | 16 | 17 | 14 |
| Profit After Tax | 27 | -0 | 16 | 54 | 34 | 44 | 45 | 45 | 52 | 53 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 27 | -0 | 16 | 54 | 34 | 44 | 45 | 45 | 52 | 53 |
| Adjusted Earnings Per Share | 5.3 | -0.1 | 2.8 | 9.6 | 5.1 | 6.7 | 6.9 | 6.8 | 7.9 | 8 |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM |
|---|---|---|---|---|---|---|
| Net Sales | 463 | 486 | 733 | 893 | 1070 | 1221 |
| Other Income | 2 | 4 | 4 | 10 | 26 | 34 |
| Total Income | 465 | 490 | 737 | 903 | 1095 | 1255 |
| Total Expenditure | 380 | 419 | 580 | 691 | 831 | 945 |
| Operating Profit | 84 | 71 | 157 | 212 | 264 | 310 |
| Interest | 26 | 39 | 44 | 42 | 26 | 6 |
| Depreciation | 26 | 31 | 36 | 39 | 42 | 49 |
| Exceptional Income / Expenses | 0 | 0 | -0 | -2 | 0 | 2 |
| Profit Before Tax | 33 | 2 | 77 | 129 | 195 | 258 |
| Provision for Tax | 3 | 4 | 26 | 56 | 19 | 64 |
| Profit After Tax | 30 | -2 | 51 | 73 | 177 | 195 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 30 | -2 | 51 | 73 | 177 | 195 |
| Adjusted Earnings Per Share | 5.8 | -0.5 | 10.1 | 12.9 | 26.9 | 29.6 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 20% | 30% | 0% | 0% |
| Operating Profit CAGR | 25% | 55% | 0% | 0% |
| PAT CAGR | 142% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 21% | NA% | NA% | NA% |
| ROE Average | 23% | 21% | 15% | 15% |
| ROCE Average | 22% | 20% | 16% | 16% |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|
| Shareholder's Funds | 237 | 239 | 294 | 366 | 1169 |
| Minority's Interest | 0 | 7 | -5 | -2 | -0 |
| Borrowings | 244 | 421 | 465 | 453 | 0 |
| Other Non-Current Liabilities | 20 | 25 | 33 | 37 | 7 |
| Total Current Liabilities | 103 | 96 | 123 | 132 | 106 |
| Total Liabilities | 603 | 789 | 909 | 986 | 1281 |
| Fixed Assets | 435 | 630 | 684 | 720 | 718 |
| Other Non-Current Assets | 35 | 46 | 44 | 57 | 154 |
| Total Current Assets | 134 | 113 | 180 | 209 | 410 |
| Total Assets | 603 | 789 | 909 | 986 | 1281 |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 8 | 7 | 18 | 103 | 134 |
| Cash Flow from Operating Activities | 74 | 123 | 137 | 117 | 115 |
| Cash Flow from Investing Activities | -43 | -296 | -85 | -104 | -76 |
| Cash Flow from Financing Activities | -32 | 185 | 33 | 18 | 128 |
| Net Cash Inflow / Outflow | -1 | 12 | 85 | 31 | 167 |
| Closing Cash & Cash Equivalent | 7 | 19 | 103 | 134 | 301 |
| # | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 5.83 | -0.45 | 10.05 | 12.9 | 26.94 |
| CEPS(Rs) | 10.92 | 5.59 | 17.16 | 19.72 | 33.4 |
| DPS(Rs) | 0 | 0 | 1 | 1 | 1 |
| Book NAV/Share(Rs) | 46.54 | 46.98 | 57.36 | 64.7 | 178.3 |
| Core EBITDA Margin(%) | 17.84 | 13.81 | 20.92 | 22.56 | 22.27 |
| EBIT Margin(%) | 12.65 | 8.34 | 16.51 | 19.16 | 20.73 |
| Pre Tax Margin(%) | 7.1 | 0.32 | 10.52 | 14.42 | 18.27 |
| PAT Margin (%) | 6.4 | -0.47 | 6.97 | 8.17 | 16.51 |
| Cash Profit Margin (%) | 12 | 5.85 | 11.91 | 12.49 | 20.48 |
| ROA(%) | 4.91 | -0.33 | 6.02 | 7.7 | 15.58 |
| ROE(%) | 12.52 | -0.97 | 19.27 | 22.18 | 23.02 |
| ROCE(%) | 11.52 | 6.91 | 16.66 | 21.07 | 22.14 |
| Receivable days | 35.17 | 24.95 | 12.37 | 15.04 | 17.56 |
| Inventory Days | 11.01 | 10.14 | 7.07 | 7.02 | 6.88 |
| Payable days | 267.8 | 217.2 | 153.57 | 153.08 | 128.08 |
| PER(x) | 0 | 0 | 0 | 0 | 44.47 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 6.72 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0.08 |
| EV/Net Sales(x) | 0.68 | 0.94 | 0.6 | 0.44 | 7.06 |
| EV/Core EBITDA(x) | 3.74 | 6.41 | 2.81 | 1.85 | 28.59 |
| Net Sales Growth(%) | 0 | 5.02 | 50.8 | 21.75 | 19.83 |
| EBIT Growth(%) | 0 | -30.81 | 198.67 | 41.24 | 29.7 |
| PAT Growth(%) | 0 | -107.75 | 2325.86 | 42.59 | 142.25 |
| EPS Growth(%) | 0 | -107.75 | 2325.71 | 28.34 | 108.82 |
| Debt/Equity(x) | 1.15 | 1.78 | 1.7 | 1.28 | 0 |
| Current Ratio(x) | 1.3 | 1.18 | 1.46 | 1.58 | 3.87 |
| Quick Ratio(x) | 1.16 | 1.04 | 1.34 | 1.44 | 3.67 |
| Interest Cover(x) | 2.28 | 1.04 | 2.76 | 4.04 | 8.42 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 |
| # | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Promoter | 40.91 | 40.91 | 40.91 | 40.91 | 40.91 | 40.91 | 40.91 |
| FII | 4.62 | 3.97 | 4.17 | 6.06 | 8.84 | 10.04 | 10.03 |
| DII | 12.69 | 13.93 | 14.16 | 13.85 | 13.46 | 12.33 | 12.22 |
| Public | 41.78 | 41.19 | 40.75 | 39.17 | 36.79 | 36.72 | 36.84 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Promoter | 2.68 | 2.68 | 2.68 | 2.68 | 2.68 | 2.68 | 2.68 |
| FII | 0.3 | 0.26 | 0.27 | 0.4 | 0.58 | 0.66 | 0.66 |
| DII | 0.83 | 0.91 | 0.93 | 0.91 | 0.88 | 0.81 | 0.8 |
| Public | 2.74 | 2.7 | 2.67 | 2.57 | 2.41 | 2.41 | 2.42 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6.56 | 6.56 | 6.56 | 6.56 | 6.56 | 6.56 | 6.56 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Sell or Purchase Share (Tentative Price)
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
You May Also Know About
